SCHEMBL1122887

SCHEMBL1122887

COC(=O)C(Cc1c[nH]c2ccc(OCc3ccccc3)cc12)NC(=O)c1cccc(OCCN(Cc2ccccc2)Cc2ccccc2)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TACR1 P25103 6/20 0.54
MEN1 O00255 2/20 0.54
KMT2A Q03164 2/20 0.54
CCKBR P32239 1/20 0.53
PPARG P37231 2/20 0.51
HSP90AA1 P07900 1/20 0.50
HSP90AB1 P08238 1/20 0.50
LTA4H P09960 1/20 0.50
PLA2G2A P14555 1/20 0.50
GPR132 Q9UNW8 1/20 0.49
LNPEP Q9UIQ6 2/20 0.48
MMP2 P08253 1/20 0.48
MMP13 P45452 1/20 0.48
MMP14 P50281 1/20 0.48
ADAM17 P78536 1/20 0.48
MAPT P10636 1/20 0.47
ERAP2 Q6P179 1/20 0.47
ERAP1 Q9NZ08 1/20 0.47
HTR1D P28221 1/20 0.47
TRPM8 Q7Z2W7 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1122892 0.94 PPARG (0.56) TACR1MEN1KMT2ACCKBRPPARG
SCHEMBL1122844 0.93 MEN1 (0.63) TACR1MEN1KMT2ACCKBRPPARG
SCHEMBL1123375 0.87 PPARG (0.65) MEN1KMT2ACCKBRPPARGHSP90AA1
SCHEMBL1122981 0.84 ITGB2 (0.52) TACR1MEN1KMT2APPARGGPR132
SCHEMBL11685799 0.80 MEN1 (0.68) TACR1MEN1KMT2APPARGHSP90AA1
SCHEMBL1123056 0.78 PPARG (0.54) MEN1KMT2APPARGLNPEPADAM17
SCHEMBL1122929 0.77 PPARG (0.59) TACR1MEN1KMT2APPARGLNPEP
SCHEMBL1122743 0.76 GPR132 (0.76) PPARGGPR132LNPEPERAP2
SCHEMBL1122705 0.76 GPR132 (0.76) PPARGGPR132LNPEPERAP2
SCHEMBL853305 0.75 LTA4H (0.69) MEN1KMT2AHSP90AA1HSP90AB1LTA4H

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1644321-B1 NEW BENZAMIDES AS PPATY MODULATORS S A L V A T LAB SA (ES) 2011-02-09 EP disclosed
US-20060160894-A1 Benzamides as ppar modulators LABORATORIOS S.A.L.V.A.T.,S.A. (ES) 2006-07-20 US disclosed
EP-1644321-A2 NEW BENZAMIDES AS PPATY MODULATORS LABORATORIOS S.A.L.V.A.T., S.A. (ES) 2006-04-12 EP disclosed
WO-2004110983-A2 NEW BENZAMIDES AS PPARϒ MODULATORS LABORATORIOS S.A.L.V.A.T., S.A. (ES) 2004-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160894-A1 Benzamides as ppar modulators PPARD, PPARA, PPARG TACR1 750/4885MEN1 4877/4885KMT2A 1515/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.